Esperion’s ‘lipid lurkers’ take on cardiovascular disease

Esperion Therapeutics has debuted a promotional push for its FDA-approved non-statin low-density lipoprotein (LDL) drugs Nexlizet and Nexletol. The campaign features “lipid lurkers,” mischievous cartoon creatures